NYSE
$3.49▼ 0.29%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $40.9MShares out 11.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
23- 5d agoAfter-hours26.10.20 05:50S-8Offering#●●●
Nasus Pharma Ltd
Nasus Pharma Ltd. has registered an additional 200,000 ordinary shares to be reserved for issuance under its 2019 Incentive Option Plan for U.S. persons. This registration is in addition to the 1,023,178 shares previously registered under the plan.…more
$3.49-0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8After-hours26.10.09 05:306-KKey event
Nasus Pharma Ltd
Nasus Pharma Ltd. announced that all agenda items, except for Proposal No. 4, were approved by shareholders at the Annual and Special General Meeting held on October 8, 2026. The results of this meeting will be incorporated into the company's future business operations and management.…more
$3.49-0.29%vs prev closeView filingShare - 9.23Pre-market26.09.23 19:143Ownership
Nasus Pharma Ltd
Elmaliah Oren, an executive at Nasus Pharma Ltd, has filed Form 3 to report their initial beneficial ownership of company securities. This filing serves as the official disclosure of the executive's equity position.…more
$3.49-0.29%vs prev closeView filingShare
22 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29Pre-market26.09.29 21:00#●●●#●●●#●●●
Nasus Pharma Initiates Phase 1 Trial for Intranasal NS003
Nasus Pharma has enrolled and dosed the first patient in its Phase 1 clinical trial for NS003, an intranasal formulation for nausea and vomiting. As the drug is in the early stages of clinical development, this milestone is considered neutral for investors.…more
$3.49-0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.14Pre-market26.09.14 21:00
●●●●●●●● ●●●●● ●●●●●●
Nasus Pharma has received FDA clearance to begin clinical trials for its intranasal epinephrine powder, NS002, designed to treat anaphylaxis. The company plans to launch a pivotal study in the fourth quarter of 2026, with top-line data expected in the first quarter of 2027.…more
$3.49-0.29%vs prev close - 9.8Pre-market26.09.08 20:30
●●●●●●●● ●●●●● ●●●●●●
Nasus Pharma announced that its management team will present and hold investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference. This event serves as a platform for corporate updates and investor relations, with no immediate impact on stock performance.…more
$3.49-0.29%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report